PULMONARY MUCORMYCOSIS AS A COMPLICATION OF SARS COV-2 PNEUMONIA - CASE REPORT AND REVIEW OF LITERATURE
Journal of General Internal Medicine
; 37:S506, 2022.
Article
in English
| EMBASE | ID: covidwho-1995821
ABSTRACT
CASE A 31-year-old woman G4P2204 was admitted with respiratory failure. Her hemoglobin was 9.7 g/dl, D-dimer 1349 ng/mL feu, procalcitonin 0.44 ng/ mL, CRP 91.4 mg/L, normal white count and nasal RT-PCR positive for COVID-19. Chest x-ray showed bilateral patchy airspace opacities. She underwent emergent C-section, was intubated and placed on mechanical ventilation, received Remdesivir, dexamethasone, vancomycin and piperacillintazobactam. On day 11, she developed bilateral pneumothorces and had chest tubes placed. She had new elevation in white blood count (16,000/ul) and inflammatory markers. She was put on extracorporeal membrane oxygenation (ECMO). Computed Tomography ( CT) chest on day 15 showed large multiloculated cavity. She underwent bronchoscopy with bronchoalveolar lavage cultures positive for Mucorales. She had CT abdomen-pelvis, CT head and nasal endoscopy without evidence of invasive disease. She was started on amphotericin B and posaconazole. She had tracheostomy on day 21 and underwent successful ECMO weaning and decannulation on day 35. Chest tubes were removed. Amphotericin B was discontinued. She was discharged on nasal cannula and oral posaconazole and continued to improve. IMPACT/DISCUSSION:
There are 6 other cases reported in literature with isolated pulmonary mucormycosis associated with SARS-CoV-2. All of these patients had clinical improvement before deteriorating again with SARS Cov-2 treatment. The timeline of new imaging findings like cavities, changing opacities, pleural effusions or bronchopleural fistula was usually 2 to 3 weeks from diagnosis of SARS-CoV-2 pneumonia. On analysis 5/7 of these patients were not diabetic, 6/7 received steroids, 3/7 received Tocilizumab and 4/7 received Remdesivir. 2 patients received surgical intervention with medical management although it did not change the outcome. Unfortunately despite aggressive medical and surgical treatment, there were poor outcomes. 4/7 patients died, 1/7 was permanently ventilator dependent and 2/7 survived. The diagnosis of isolated pulmonary mucormycosis is challenging. This might be secondary to hesitance of invasive diagnostic tests like bronchoscopy, lack of rapid diagnostic tests and fewer autopsies. Amphotericin B, posaconazole and isavuconazole remain the main treatment options along with surgical debridement of necrotic tissue. The pathology of mucormycosis in COVID-19 has been attributed to impaired T-cell function, impaired phagocytosis and more availability of fungal heme oxygenase which facilitates iron uptake for its metabolism. Glucocorticoids, IL-6 inhibitors and monoclonal antibodies further increase the risk of secondary infections.CONCLUSION:
Mucormycosis is a lifethreatening disease with high morbidity and mortality. Based on our case and literature review, it is important to have high index of suspicion for pulmonary mucormycosis in patients who are recently treated with immunosuppressants for SARS-CoV-2 pneumonia and suddenly deteriorate after treatment.
amphotericin B; D dimer; dexamethasone; endogenous compound; glucocorticoid; heme oxygenase; hemoglobin; immunosuppressive agent; interleukin 6; isavuconazole; posaconazole; procalcitonin; remdesivir; tocilizumab; vancomycin; abdomen; adult; artificial ventilation; autopsy; bronchopleural fistula; bronchoscopy; cell function; chest tube; complication; computer assisted tomography; conference abstract; coronavirus disease 2019; decannulation; diabetes mellitus; diagnosis; drug combination; drug therapy; extracorporeal oxygenation; female; human; iron transport; leukocyte count; literature; lung lavage; metabolism; morbidity; mortality; mucormycosis; nasal cannula; nasal endoscopy; nonhuman; outcome assessment; pelvis; phagocytosis; pleura effusion; respiratory failure; secondary infection; Severe acute respiratory syndrome coronavirus 2; surgery; surgical debridement; systematic review; T lymphocyte; thorax radiography; tracheostomy; weaning
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Language:
English
Journal:
Journal of General Internal Medicine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS